These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33935492)

  • 1. Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells.
    Liu P; Huang W; Ding Y; Wu J; Liang Z; Huang Z; Xie W; Kong H
    Drug Des Devel Ther; 2021; 15():1653-1666. PubMed ID: 33935492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasudil dichloroacetate (FDCA), an orally available agent with potent therapeutic efficiency on monocrotaline-induced pulmonary arterial hypertension rats.
    Qi L; Lv T; Cheng Y; Yu M; Han H; Kong H; Xie W; Wang H; Zhang Y; Huang Z
    Bioorg Med Chem Lett; 2019 Jul; 29(14):1812-1818. PubMed ID: 31088713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition.
    Yu M; Peng L; Liu P; Yang M; Zhou H; Ding Y; Wang J; Huang W; Tan Q; Wang Y; Xie W; Kong H; Wang H
    Drug Des Devel Ther; 2020; 14():1191-1202. PubMed ID: 32256050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery.
    Rashid J; Nahar K; Raut S; Keshavarz A; Ahsan F
    Mol Pharm; 2018 May; 15(5):1755-1765. PubMed ID: 29528655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
    Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
    Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension.
    Li C; Liu PP; Tang DD; Song R; Zhang YQ; Lei S; Wu SJ
    Pulm Pharmacol Ther; 2018 Jun; 50():111-122. PubMed ID: 29673911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Dichloroacetate and Atorvastatin Regulates Excessive Proliferation and Oxidative Stress in Pulmonary Arterial Hypertension Development via p38 Signaling.
    Li T; Li S; Feng Y; Zeng X; Dong S; Li J; Zha L; Luo H; Zhao L; Liu B; Ou Z; Lin W; Zhang M; Li S; Jiang Q; Qi Q; Xu Q; Yu Z
    Oxid Med Cell Longev; 2020; 2020():6973636. PubMed ID: 32617141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
    Zhang L; Wang Y; Wu G; Rao L; Wei Y; Yue H; Yuan T; Yang P; Xiong F; Zhang S; Zhou Q; Chen Z; Li J; Mo BW; Zhang H; Xiong W; Wang CY
    Cell Prolif; 2020 Feb; 53(2):e12742. PubMed ID: 31943454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
    Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
    Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulforaphane prevents right ventricular injury and reduces pulmonary vascular remodeling in pulmonary arterial hypertension.
    Kang Y; Zhang G; Huang EC; Huang J; Cai J; Cai L; Wang S; Keller BB
    Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H853-H866. PubMed ID: 32108526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
    Chen XY; Dun JN; Miao QF; Zhang YJ
    Pharmacology; 2009; 83(2):67-79. PubMed ID: 19052484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
    Oka M; Homma N; Taraseviciene-Stewart L; Morris KG; Kraskauskas D; Burns N; Voelkel NF; McMurtry IF
    Circ Res; 2007 Mar; 100(6):923-9. PubMed ID: 17332430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of mitochondrial fragmentation in microvascular endothelial cells isolated from the SU5416/hypoxia model of pulmonary arterial hypertension.
    Suresh K; Servinsky L; Jiang H; Bigham Z; Zaldumbide J; Huetsch JC; Kliment C; Acoba MG; Kirsch BJ; Claypool SM; Le A; Damarla M; Shimoda LA
    Am J Physiol Lung Cell Mol Physiol; 2019 Nov; 317(5):L639-L652. PubMed ID: 31461316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maxingxiongting mixture attenuates hypoxia pulmonary arterial hypertension to improve right ventricular hypertrophy by inhibiting the rho-kinase signaling pathway.
    An X; Li S; Weng X; Wang X; Wu H; Zhang X; Gao J; Yang R; Peng B; Li S; Weng X; Wang X; Zhang X; Gao J
    J Tradit Chin Med; 2020 Dec; 40(6):992-998. PubMed ID: 33258351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astragaloside IV attenuates hypoxia‑induced pulmonary vascular remodeling via the Notch signaling pathway.
    Yao J; Fang X; Zhang C; Yang Y; Wang D; Chen Q; Zhong G
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats.
    Li F; Xia W; Li A; Zhao C; Sun R
    Pharmacol Res; 2007 Jan; 55(1):64-71. PubMed ID: 17127075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactive oxygen species induced Ca
    Suresh K; Servinsky L; Jiang H; Bigham Z; Yun X; Kliment C; Huetsch J; Damarla M; Shimoda LA
    Am J Physiol Lung Cell Mol Physiol; 2018 May; 314(5):L893-L907. PubMed ID: 29388466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
    Sun XQ; Peters EL; Schalij I; Axelsen JB; Andersen S; Kurakula K; Gomez-Puerto MC; Szulcek R; Pan X; da Silva Goncalves Bos D; Schiepers REJ; Andersen A; Goumans MJ; Vonk Noordegraaf A; van der Laarse WJ; de Man FS; Bogaard HJ
    Am J Respir Cell Mol Biol; 2021 Mar; 64(3):331-343. PubMed ID: 33264068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
    Chaumais MC; Djessas MRA; Thuillet R; Cumont A; Tu L; Hebert G; Gaignard P; Huertas A; Savale L; Humbert M; Guignabert C
    Cardiovasc Res; 2021 Apr; 117(5):1391-1401. PubMed ID: 32653925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Na+/H+ exchanger contributes to increased smooth muscle proliferation and migration in a rat model of pulmonary arterial hypertension.
    Huetsch JC; Jiang H; Larrain C; Shimoda LA
    Physiol Rep; 2016 Mar; 4(5):. PubMed ID: 26997630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.